Sign in
CompletedPhase 2

Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps

Key facts

Who runs it
Guangdong Hengrui Pharmaceutical Co., Ltd
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
114 people enrolled
Started
4 Sept 2023
Ended
21 Jan 2026
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • SHR-1905 Injection
  • SHR-1905 Placebo Injection
Record updated
22 July 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 32 criteriaShow less

Who can take part

  • Weight ≥40kg
  • Diagnosed with chronic rhinosinusitis with nasal polyps (CRSwNP)
  • Bilateral nasal polyps at screening and baseline, total NPS ≥5, ≥2 points for each nostril
  • NCS ≥2 at screening and baseline
  • SNOT-22≥20 at screening period and baseline
  • Recorded persistent NP symptoms for over 4 weeks prior to screening
  • Subjects received standard therapy with intranasal corticosteroids (INCS) and remained stable during the 4 weeks prior to randomization
  • NP surgery in the past and/or ACERS treated with SCS occurred within 2 years before randomization (or with contraindications/ intolerances)

Who cannot take part

  • Concomitant with immunodeficiency
  • Concomitant with contraindications or not suitable for nasal endoscopy
  • Infection within 2 weeks prior to screening to randomization that is clinically significant and/or should be treated with systemic antibiotics
  • Uncontrolled epistaxis within 4 weeks prior to randomization
  • Major surgery performed within 3 months prior to randomization, or surgery planned during the study, or treatments that may affect evaluations according to investigators
  • Parasitic infection within 6 months before randomization
  • Sinus or intranasal surgery (except for diagnostic biopsy) within 6 months prior to randomization, or changes in the nasal walls caused by sinus or intranasal surgery that made NPS evaluation impossible
  • Concomitant with active hepatitis B, positive hepatitis C virus antibodies, positive human immunodeficiency virus antibodies, or positive treponema pallidum antibodies
  • Transfusion of blood products or immunoglobulin within 4 weeks prior to randomization
  • SCS or additional INCS use within 4 weeks before randomization, or planned use during treatment period
  • Regular use of decongestants (local or systemic) within 4 weeks before randomization, except for during the endoscopic procedure
  • Adnimistration of live vaccine or viral vector vaccine within 4 weeks before randomization
  • Allergen immunotherapy within 8 weeks before randomization
  • Substance abuse, drug abuse, and/or excessive alcohol consumption within 1 year prior to randomization
  • Uncontrolled hypertension
  • Uncontrolled diabetes
  • Malignancies diagnosed within 5 years before randomization (except those with a low risk of metastasis or death)
  • Abnormalities of laboratory tests at screening or baseline
  • Prolonged QTc interval (>450ms for male and >470ms for female) or other clinically significant abnormal results of ECG at screening or baseline that may cause significant safety risks to subjects
  • Any comorbidities that may affect the efficacy evaluation of nasal polyps
  • Any comorbidities except for asthma that may affect blood EOS levels
  • FEV1 before the use of bronchodilator (pre-BD) was less than 50% at screening
  • Smoking history ≥10 pack-years, smoking at screening, or smoking cessation less than 6 months at screening
  • Pregnancy (including positive pregnancy test at screening or baseline), lactation, or pregnancy plan during study period

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study is being conducted to evaluate the efficacy, and safety of SHR-1905 injection in subjects with chronic rhinosinusitis with nasal polyps (CRSwNP), as well as to explore the reasonable dosage of SHR-1905 injection for CRSwNP.

The 4 groups in the trial

  • Treatment group A: SHR-1905 Injection(dose 1)Treatment being tested

    Treatment: SHR-1905 Injection

  • Treatment group B: SHR-1905 Injection(dose 2)Treatment being tested

    Treatment: SHR-1905 Injection

  • Treatment group C: SHR-1905 Injection(dose 3)Treatment being tested

    Treatment: SHR-1905 Injection

  • Placebo GroupPlacebo, for comparison

    Treatment: SHR-1905 Placebo Injection

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Efficacy and Safety Study of SHR-1905 in Patiens With Chronic Rhinosinusitis With Nasal Polyps
Record updated
22 July 2026